Boehringer Says Teva's Diabetes Drug Will Infringe IP
Boehringer has asked a London court to stop Teva launching its generic version of diabetes drug empagliflozin, arguing that the Israeli drugmaker is set to infringe extended patent protections covering the...To view the full article, register now.
Already a subscriber? Click here to view full article